Posts by vimelanie

Deal Away, But Don’t Forget What Payers Think

Posted on Thursday, January 10, 2013

As pharma and biotech execs at JP Morgan in San Francisco craft the next round of life- and/or growth-extending deals, they’ll hopefully remember that the key issue is now reimbursability, not...

Learn More

As Pressure Builds on US Prices, Is Pharma Ready?

Posted on Friday, December 14, 2012

Free drug pricing in the US has fewer than five years to run, thanks to mounting pressure on health care spend and resulting efficiency drives.  That’s the message to pharma investors, be it from...

Learn More

HTA Has To Harmonize. It’s A Money Thing.

Posted on Thursday, November 29, 2012

There was bad news and some less bad news for drug firms at the recent NextLevel Pharma Pharmaccess Leaders’ Forum in Berlin, Germany.  The bad news: added-benefit hurdles, in the form of Health...

Learn More

Want Better Access? Then Take Some More Risk

Posted on Tuesday, November 20, 2012

Biopharma is an industry seeped in an above-average concentration of risk. Scientific, clinical and regulatory uncertainties add to more typical commercial and market-driven risks. Given that, you’d...

Learn More

Drug Approvals Need Shades Of Grey

Posted on Monday, November 12, 2012

FDA’s Endocrinologic and Metabolic drugs advisory committee on Nov. 8 voted 8-4 in favor of recommending Novo’s latest insulin degludec (Tresiba) for approval. The detailed debate and...

Learn More